Plaintiffs allege that Bristol-Meyers Squibb Company unlawfully monopolized the United States market for cisplatin, a cancer drug which Bristol sells under the brand name Platinol, in violation of federal antitrust laws.  Cohen Milstein’s investigation and prosecution of this litigation on behalf of direct purchasers of Platinol lead to a settlement of $50 million in November 2004.  Cohen Milstein served as lead counsel.